Genesis AEC Highlights PharmaWater Pro® Modeling Capability for Early Stage Pharmaceutical Water System Design

Platform helps manufacturers evaluate sustainability, utilities, and lifecycle costs before committing to major infrastructure

Baxfendy’s FDA Approval Puts AstraZeneca on Track for a $5 Billion Cardiometabolic Opportunity

AstraZeneca has received FDA approval for Baxfendy, a first-in-class treatment for hypertension, marking a significant milestone in its cardiometabolic growth strategy. The company believes the drug could address a major unmet need among millions of patients with uncontrolled blood pressure and has the potential to generate up to $5 billion in peak annual revenue. AstraZeneca is also evaluating Baxfendy for chronic kidney disease, heart failure, and other related conditions. The approval strengthens the company's position in cardiovascular and metabolic care while supporting its long-term growth ambitions.

Acute Patients Embrace At-Home Monitoring, Emphasizing Device Comfort and Ease of Use as Driving Adoption

Vivalink’s latest survey highlights key drivers for patient compliance and retention in acute remote care programs

Moderna and Merck Report Five-Year Melanoma Data Showing Durable Benefit of Personalized Cancer Vaccine With KEYTRUDA

Moderna and Merck shared 5-year results from the KEYNOTE-942 study showing that their personalized mRNA cancer vaccine, intismeran autogene, combined with KEYTRUDA, significantly improves outcomes for high-risk melanoma patients. The treatment reduced the risk of cancer recurrence or death by 49% and distant metastasis or death by 59% compared to KEYTRUDA alone. It also showed encouraging overall survival trends and stronger immune responses driven by tumor-targeted T-cells. The therapy remained safe over long-term follow-up with mostly mild side effects, highlighting the potential of personalized cancer vaccines in future oncology care.

Sygnature Discovery collaborates with DaltonTx to advance AI-enabled drug discovery capabilities

Verista Announces Appointment of Michael Laferrera as Chief Executive Officer

Verista names seasoned healthcare and pharma services leader as CEO to drive strategic growth, innovation, and operational excellence.

PubHive Named Best Niche Literature Software Company 2026 – UK

PubHive wins 2026 UK award for AI-powered literature workflows supporting evidence, safety, regulatory, and life sciences teams.

TeleTracking Brings Real-Time Operational Intelligence Beyond the Hospital Walls with Operations IQ(R) Ambulatory

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration

CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanized monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months

Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights

IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.

ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection

ClearNote Health today announced a $52M Series D financing alongside the appointment of Kevin Keegan as President and COO.

CellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Network

CellCarta has announced a Strategic Partnership with Sonic to launch the first commercial laboratory relationship in CellCarta’s Lab Network strategy.

Baptist Health South Florida and The START Center for Cancer Research Announce Strategic Partnership to Expand Patient Access to Early-Phase Cancer Trials

New START site to be established in collaboration with Baptist Health Herbert Wertheim Cancer Institute will bring novel oncology therapies closer to patients across South Florida.

Syncell Launches High-Precision Proteomics Discovery Service Powered by Microscoop® Mint Platform

Syncell announced the commercial launch of Syncell Discovery Services, a new sample-to-discovery offering that gives biopharma, translational, and academic researchers direct access to insights generated by the company’s unbiased nanoscopic Microscoop Mint platform.

‘Biopharma innovators must widen CDMO networks to accelerate development’ says Shilpa Biologicals CEO ahead of BIO San Diego

Ahead of BIO San Diego, Shilpa Biologicals urges biotech innovators to engage CDMO partners earlier and look beyond large-scale providers. Over-relying on a narrow network of large CDMOs increases the risk of scope creep, severe clinical trial delays, and budget overruns of up to 40%. Conversely, incorporating smaller CDMOs can lower costs and accelerate timelines from discovery to clinic by several months.

Biopharma PEG Highlights High-Purity DSPE-PEG Derivatives for Advanced Nanocarrier Drug Delivery Systems

Quotient Sciences Advances AI-Designed Drug Product into Clinical Development

Ambience Healthcare Expands Chart-Aware Intelligence to Full Inpatient Workflow

Building on its chart awareness platform, Ambience now delivers clinical context across the full hospital stay, from admission through discharge

Ardena appoints Ariane de Ganck as Chief Scientific Officer

Pfizer and Innovent Biologics Enter $10.5 Billion Oncology Drug Development Partnership for 12 Cancer Programs

Pfizer and Innovent Biologics have signed an oncology partnership worth up to $10.5 billion to develop a pipeline of 12 cancer programs focused on antibody-drug conjugates (ADCs) and multispecific antibodies. Pfizer will pay $650 million upfront, with additional milestone-based payments tied to development and commercialization success. The collaboration combines Innovent’s early-stage research capabilities with Pfizer’s global development and commercialization expertise to accelerate the delivery of new cancer therapies worldwide.